Technology | Biopsy Systems | February 02, 2016

Focal Healthcare Receives FDA Clearance for MR-Ultrasound Fusion Prostate Biopsy Device

Technology joins previously acquired MR images to live ultrasound for highly targeted biopsies

Focal Healthcare, Fusion Bx, FDA clearance, MR-ultrasound fusion, prostate biopsy

February 2, 2016 — Focal Healthcare Inc. announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for their targeted prostate biopsy device, Fusion Bx. With the availability of Fusion Bx, clinicians are no longer limited to the traditional systematic biopsy approach for diagnosis, but can instead accurately take targeted biopsies directly from suspicious cancer regions within the prostate using magnetic resonance imaging (MRI)-ultrasound fusion technology.

MRI has the ability to see tumors in the prostate that ultrasound alone cannot. Thus, by fusing previously acquired MR images to live ultrasound, clinicians can target suspicious tumors when taking biopsy samples. Fusion biopsy has been shown to detect high-grade cancer in 30 percent more men compared to traditional systematic biopsy. In addition, by accurately determining the location and extent of the cancer, this procedure allows clinicians to confidently monitor cancer progression over time and prescribe the appropriate course of treatment to patients with varying grades of cancer.

With this clearance, Focal Healthcare plans to make this procedure accessible to all patients.

The device has been developed in close collaboration with clinicians including Winston Barzell, M.D., Florida State University (Sarasota);  Daniel Margolis, M.D., David Geffen School of Medicine at UCLA (Los Angeles); and Michael McGuire, M.D., NorthShore University Health System (Chicago). Barzell is currently conducting a clinical trial with Fusion Bx at 21st Century Oncology in Sarasota, Florida.

"In contrast to systematic 'blind' biopsies, targeted fusion biopsies reliably identify clinically significant cancers, while reducing the random detection of insignificant cancers that are frequently at risk of over-treatment. Fusion Bx is an exciting, innovative technology that will provide busy clinicians access to a state-of-the-art, user-friendly fusion biopsy system which can be seamlessly introduced to the routine urology office workflow," said Barzell

Fusion Bx is FDA 510k cleared for use by physicians for enhanced visualization of ultrasound imaging of the prostate in clinic and hospital settings. It provides 2-D and 3-D image visualization including review, manipulation and analysis tools.

For more information: www.focalhealthcare.com

Related Content

ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
U.K.'s NICE Supports Use of Hydrogel Spacer in Prostate Cancer Treatement
News | Patient Positioning Radiation Therapy | September 08, 2017
Augmenix Inc. announced that the National Institute for Health and Care Excellence (NICE) in the U.K. has issued...
Augmenix Announces Medicare Administrative Contractor Palmetto Coverage for SpaceOAR Hydrogel
News | Patient Positioning Radiation Therapy | September 05, 2017
Augmenix Inc. announced that Palmetto GBA LLC — the Medicare Administrative Contractor (MAC) covering North Carolina,...
Hologic Announces Availability of Brevera Breast Biopsy System With CorLumina Imaging Technology
Technology | Breast Biopsy Systems | August 31, 2017
Hologic Inc. announced U.S. commercial availability of the Brevera breast biopsy system with CorLumina imaging...
UCLA Study Offers Roadmap to Personalized Therapies for Sarcoma
News | Oncology Diagnostics | August 22, 2017
A new UCLA study is the first to identify patient and tumor characteristics that predict the successful creation of...
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
Synergy Radiology Associates Employs UroNav Fusion Biopsy System for Better Prostate Cancer Diagnosis
News | Biopsy Systems | July 17, 2017
Radiologists from Synergy Radiology Associates (SRA) in Houston are using the power of 3-D medical imaging and...
Overlay Init